Detailed Information
Cited 0 time in 
Cited 37 time in 
Cited 37 time in
Metadata Downloads
New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2
- Authors
- Lim, Jung-Ah; Lee, Soon-Tae; Moon, Jangsup; Jun, Jin-Sun; Park, Byeong-su; Byun, Jung-Ick; Sunwoo, Jun-Sang; Park, Kyung-Il; Jung, Keun-Hwa; Jung, Ki-Young; Lee, Sang Kun; Chu, Kon
- Issue Date
- 15-Oct-2016
- Publisher
- Elsevier BV
- Keywords
- Encephalitis; Autoimmune encephalitis; Low-dose IL-2; Regulatory T cell
- Citation
- Journal of Neuroimmunology, v.299, pp 107 - 111
- Pages
- 5
- Journal Title
- Journal of Neuroimmunology
- Volume
- 299
- Start Page
- 107
- End Page
- 111
- ISSN
- 0165-5728
1872-8421
- Abstract
- Low-dose interleukin-2 (IL-2) restores the balance of regulatory and effector T cells. We aimed to determine the feasibility of low-dose IL-2 as a treatment for refractory autoimmune encephalitis (AE). Ten patients who had received low-dose IL-2 were retrospectively identified. We observed an improvement in the modified Rankin Scale scores of six patients at the last follow-up compared with the scores at the initiation of low-dose IL-2 (p = 0.014). One patient experienced treatment-related grade 3 neutropenia. Overall, low-dose IL-2 is a feasible and relatively safe treatment for AE patients who are refractory to the first- and second-line immunotherapies. (C) 2016 Elsevier B.V. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.